After years of losses, Legend Biotech’s new cancer drug Cavykti offers it a chance to finally start contributing revenue to its parent, Genscript Biotech. Some analysts believe Genscript may have ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results